Search for a trial

A phase II prospective imaging study evaluating the utility of pre-treatment zirconium-89 labelled trastuzumab PET/CT and an early FDG-PET/CT response to identify patients with advanced HER-2 positive breast cancer unlikely to benefit from a novel anti-HER2 therapy: T-DM1

The primary objective (on lesion-based analysis) is to show that pre-treatment 89Zr-trastuzumab PET/CT is able to select lesions not responding morphologically from treatment with T-DM1 (applying RECIST 1.0 criteria)Secondary Objectives and…

Zirconium-89 Trastuzumab tracer uptake in metastatic breast cancer: A pilot study.

Primary Objectives:Use 89Zr-Trastuzumab to characterise the in vivo biodistribution using PET imaging in the primary tumour and distant metastases.Comparie the uptake in patients with Her2/neu positive breast cancer to patients with HER2/neu…